NON-SMALL CELL LUNG CANCER (NSCLC)

This study is comparing a new targeted drug called MK-2870 (sacituzumab tirumotecan) against standard chemotherapy for people with advanced non-small cell lung cancer that has specific genetic changes and has stopped responding to previous treatments. The trial will enroll 556 pa…

This is a first-in-human study testing a new oral drug called NX-1607 in adults with advanced cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the body handles the drug, both alone and combined with a common chemot…

This study is comparing two different drug combinations for people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C) and low levels of a protein called PD-L1. About 750 participants will be randomly assigned to receive either a new targeted d…

This study is testing a new drug called GTAEXS617 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors in cancers like head & neck, lung, pancreatic, ovarian, and bre…

This study is testing a new type of cell therapy for people with advanced solid tumors that have stopped responding to standard treatments. Doctors will analyze a patient's tumor to select a specific target, then infuse specially engineered immune cells (CAR-NK cells) from a heal…

This study is testing a new oral medication called STX-241 for people with advanced non-small cell lung cancer (NSCLC) that has continued to grow despite treatment with standard targeted drugs (EGFR TKIs). The main goals are to find a safe and effective dose and to see if the dru…

This is an early-stage study testing a new drug called MT-4561 in people with various advanced solid tumors who have run out of standard treatment options. The main goals are to find a safe dose, see how the body processes the drug, and check for any early signs that it might hel…

This study is testing a new oral medication called RMC-6236 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers, that have specific RAS mutations. The main goals are to find a safe and effective dose and to see if the drug can help control the…

This study is testing an experimental oral medication called JYP0015 in adults with advanced cancers that have specific RAS mutations, including pancreatic, lung, and colorectal cancers. The trial aims to find a safe dose and see if the drug can shrink tumors in patients who have…

This study is testing new combinations of experimental drugs for people with advanced solid tumors that have specific RAS mutations. Researchers want to see if combining a new type of drug called a RAS(ON) inhibitor with another cancer drug called ivonescimab is safe and can help…

This early-phase study is testing the safety and tolerability of gilteritinib, a drug already approved for a type of leukemia, in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) whose cancer has stopped responding to prior ALK inhibitor treatments. About 40 p…

This study is testing an experimental drug called M9140 in people with advanced gastric, lung, or pancreatic cancer that has stopped responding to standard treatments. The trial aims to see if M9140 can shrink tumors and is safe for patients. It will enroll about 250 adults whose…

This is a first-in-human study to test the safety and early signs of effectiveness of a new drug called STRO-004 in adults with advanced solid tumors that have come back or stopped responding to other treatments. The trial will test STRO-004 alone and in combination with an exist…

This study is testing whether a new drug called MK-2870 works better than standard chemotherapy for people with a specific type of advanced lung cancer. It is for adults whose cancer has a genetic change called EGFR and has continued to grow despite previous targeted therapy. The…

This study is testing a vaccine designed to teach the body's immune system to recognize and fight non-small cell lung cancer. It is for patients with early-stage or locally advanced lung cancer who have recently finished standard treatment. The main goal is to see if the vaccine …

This early-stage study is testing a new drug called RMC-5127 in adults with advanced cancers that have a specific genetic change called KRAS G12V. The main goals are to find a safe dose and see how the body processes the drug, both when given alone and when combined with other ca…

This study is testing whether a drug called taletrectinib can prevent early-stage lung cancer from returning after surgery. It will compare the drug to a placebo (sugar pill) in about 180 patients whose cancer has a specific genetic feature called ROS1-fusion. The main goal is to…

This early-stage study is testing a new drug called GI-108 in people with advanced or spreading solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The main goals are to find a safe dose and see if the drug shows any signs of helping to shrink tumors. The…

This program provides access to the drug ceritinib for patients with ALK-positive cancers, including lung cancer and pediatric tumors, when no other treatments are available. It is for people who cannot join regular clinical trials and have serious or life-threatening conditions.…

This study is testing whether adding a new experimental drug called WSD0922-FU to an existing lung cancer medication (osimertinib) is safe and can help control advanced non-small cell lung cancer. It is for patients whose cancer has spread or has developed specific genetic change…

This early-stage study is testing a new drug called BMS-986523, both alone and combined with other cancer treatments, in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to check if the drug is safe, how the body processes it,…

This is the first study in people testing a new cancer drug called KO-2806. It aims to find a safe dose and see if the drug can help control advanced solid tumors, including certain lung, colorectal, pancreatic, and kidney cancers. The study will test the drug by itself and combi…

This study is testing if a new two-drug combination helps people with a specific type of advanced lung cancer live longer than the current standard single-drug treatment. It will involve about 614 adults whose cancer has spread and who have not yet received treatment for it. The …

This study is testing whether radiation followed by two drugs (durvalumab and ceralasertib) can help control lung cancer that has returned in the chest area after previous treatment. The trial is for stage III non-small cell lung cancer patients whose cancer progressed despite re…

This early-stage study is testing a new drug, IDE892, both alone and in combination with another drug called IDE397. It is for adults with advanced solid tumors that have a specific genetic change called MTAP deletion and have stopped responding to standard treatments. The main g…

This study is testing two new drugs, elironrasib and daraxonrasib, for people with advanced lung, colorectal, or pancreatic cancer that has a specific genetic change called KRAS G12C. The main goals are to find safe doses and see if the drugs, given alone or together, can shrink …

This is the first-ever study in humans of a new experimental drug called TH9619 for people with advanced solid tumors. The trial aims to find a safe and effective dose while checking how the body processes the drug and whether it shows signs of fighting cancer. It's open to adult…

This program provides eligible patients with non-small cell lung cancer access to an investigational drug called telisotuzumab vedotin before it receives full regulatory approval. It is designed for patients who have no other suitable treatment options and do not qualify for ongo…

This study is testing a new drug called XL092, both by itself and in combination with other immunotherapy drugs, for people with advanced solid tumors that cannot be removed by surgery. The main goals are to find safe doses and see if the treatments can shrink tumors or slow thei…

This study is testing whether a new drug called Rina-S can help control advanced non-small cell lung cancer. About 240 people worldwide with this type of lung cancer will receive the drug directly—no one gets a placebo. Researchers will monitor how well the drug shrinks tumors an…

This is the first human study of an experimental drug called BMS-986463 for people with advanced ovarian, uterine, or lung cancers. The main goal is to find safe dose levels and see how the body processes the drug. Researchers will enroll about 240 participants to monitor side ef…

This study is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in people with advanced solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors and control the disease in people who have already tried at l…

This study is testing whether a new targeted drug called datopotamab deruxtecan works better than the standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer that has worsened after initial treatment. It will enroll 400 participants whose cancer tests …

This is the first study in people to test a new drug called LB-LR1109. The main goal is to find a safe and tolerable dose for patients with advanced or metastatic solid tumors, including lung, head and neck, kidney, bladder cancers, and melanoma. The study will test the drug alon…

This clinical trial is testing several new experimental drugs designed to target specific genetic mutations (called RAS mutations) found in advanced non-small cell lung cancer. The study will involve 616 adults whose cancer has progressed despite standard treatments. Researchers …

This study is testing whether genetic information for advanced non-small cell lung cancer can be reliably obtained from a simple lung wash procedure instead of an invasive tissue biopsy. Researchers will collect fluid from a routine bronchoscopy and analyze tiny particles called …

This study is testing a new fluorescent dye called LS301-IT to see if it helps surgeons better identify and remove lung cancer tissue during minimally invasive surgery. The dye is given by IV before surgery and is designed to make cancer cells glow under special camera imaging. T…

This study is monitoring the safety of the lung cancer drug Alunbrig (brigatinib) in real-world use in Japan. It will follow 500 patients with a specific advanced lung cancer for one year to track side effects, with a special focus on lung-related problems. The goal is to gather …

This study aims to understand what patients and their doctors value most when choosing treatments for early-stage, operable lung cancer. Researchers will conduct short interviews with 55 patients and physicians from the US, Germany, and Japan. The goal is to gather insights to he…

This early-stage study aims to understand the safety and imaging properties of an experimental radioactive tracer called RAD301. The research involves 9 participants, including both healthy volunteers and people with specific cancers like pancreatic, lung, or ovarian cancer. Part…